Outperformance Rating Returned to Kite Pharma
Published By : 18 Aug 2015 | Published By : QYRESEARCH
The stock “outperform” rating has been reassigned to Kite Pharma by the analysts working at research firm Mizuho on Monday. Kite Pharma today has a US$90 target price on their own stock. The target price set by Mizuho points to a possible upside of 49.20% from Kite’s last closing.
Numerous equities analysts have commented on Kite Pharma recently. A coverage was initiated by Maxim Group on Thursday for Kite Pharma shares. They set a buy rating along with a price target of US$87 on their stocks. The shares were raised by Vetr for Kite Pharma to show a “strong buy” stance in August from an older “buy” rating.
Another analyst firm, Cowen and Company, reconfirmed the “outperform” rating on Kite Pharma shares in late June. Standpoint Research issued a “buy” rating of US$100 stock price objective of Kite Pharma.
Another market research firm, Jefferies Group, reestablished their “buy” rating for Kite Pharma stocks at a price target of US$83 in June. In total, a research analyst for equities has given the stocks a hold rating, nine have rated “buy” for the Kite Pharma stocks, while one analyst has rated “strong buy”.
The consensus rating of the company is therefore “buy” with a consensus price target of US$84.02.
The firm traded up 4% in Monday’s mid-day trading. It reached a stock value of US$60.32 with a trading volume of 2,653,251 shares. Market cap for the stock has risen to US$2.64 billion.
The 12 month low and the 12 month high for Kite Pharma are US$21.76 and US$89.21. The 50 day moving average of the stock is US$68. Kite Pharma stock also has a US$62.14 200 day moving average.